Up
until now, no known vaccine has been developed that will make cure as against
the novel coronavirus 2019 disease or COVID-19.
Advanced
countries are racing against time to find a cure as currently more than half
million has been infected with the disease that came from Wuhan, China.
On
March 28, Japan Prime Minister Shinzo Abe in a press conference anti-drug
Avigan has attracted attention from many countries. Abe said that clinical
trial process required for formal approval of the drug as treatment for the novel
coronavirus 2019 will be launched.
Japan Prime Minister Shinzo Abe |
The
Prime Minister said Japan wouls be willing to work with other countries to
expand clinical research and start increasing drug production.
“Very promising po siya, mukha po
talaga siyang sa ngayon sa mga anti-viral ay ito po ang parang medyo directed
po ang treatment towards talagang [sa] COVID-19,” Food and Drug
Administration (FDA) director general Health Undersecretary Eric Domingo said
in an interview with Dobol B sa News TV.
“Of course… this is a very early
development drug, at nakita po na meron siyang positive response sa mga
pasyente sa kanya,” he explained. “Kasi nga dinedevelop pa, wala pa po
siyang production in commercial quantity pero tinitingnan din po natin kung
pano siya maipapasok sa Pilipinas.”
Avigan
is the brand name for anti-flu drug favipiravir. It s one of the drugs being
tested worldwide as treatment for COVID-19, the other one is chloroquine, which
is originally made to treat malaria.
What can you say about this?
Share us your thoughts by simply
leaving on the comment section below. For more news updates, feel free to visit
our site often.
Stay updated with today's relevant
news and trends by hitting the LIKE button.
Thanks for dropping by and reading
this post.
Report from mntfo
Disclaimer: Contributed articles does not reflect the view of THE
PH CHRONICLES. This website cannot guarantee the legitimacy of some of
the information contributed to us. You may do additional research if you find
some information doubtful. No part of this article maybe reproduced without permission from this
website.
0 Comments